(8ci,9ci)-1H-咪唑并[4,5-f]喹啉 | 233-55-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: (8ci,9ci)-1H-咪唑并[4,5-f]喹啉
• 英文名称: 1H-Imidazo[4,5-f]quinoline(8CI,9CI)
• 英文别名: imidazo<4,5-f>quinoline
• CAS: 233-55-6
• 化学式: C₁₀H₇N₃
• mdl: MFCD18449132
• 分子量: 169.186
• InChiKey: UYVFEZBIQHCLBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.42
• 重原子数：
  13.0
• 可旋转键数：
  0.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.57
• 氢给体数：
  1.0
• 氢受体数：
  2.0

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  9-chloroimidazo[4,5-f]quinoline 在 镍 sodium hydroxide 、 氢气 作用下， 以 乙醇 为溶剂， 以56%的产率得到(8ci,9ci)-1H-咪唑并[4,5-f]喹啉
  参考文献：
  名称：

  Milata, Viktor; Ilavsky, Dusan; Lesko, Jan, Collection of Czechoslovak Chemical Communications, 1988, vol. 53, # 5, p. 1068 - 1077

  摘要：

  DOI：

文献信息

• Mild and General One-Pot Reduction and Cyclization of Aromatic and Heteroaromatic 2-Nitroamines to Bicyclic 2H-Imidazoles
  作者：Emily Hanan、Bryan Chan、Anthony Estrada、Daniel Shore、Joseph Lyssikatos

  DOI：10.1055/s-0030-1259007

  日期：2010.11

  A one-pot procedure for the conversion of aromatic and heteroaromatic 2-nitroamines into bicyclic 2H-benzimidazoles is described. The procedure employs formic acid, iron powder, and an additive such as NH4Cl to reduce the nitro group and effect the imidazole cyclization with high-yielding conversions generally within one to two hours. The compatibility with a wide range of functionality demonstrates the general utility of this procedure.

  描述了一种将芳香和杂芳香2-硝基胺转化为双环2H-苯并咪唑的一锅法步骤。该步骤采用甲酸、铁粉以及NH4Cl等添加剂来还原硝基并实现咪唑环化，通常在一到两小时内完成高产率的转化。其广泛的官能团兼容性显示了该步骤的普遍实用性。
• Thiazolyl-benzimidazoles
  申请人：Boylan John Frederick

  公开号：US20070203210A1

  公开（公告）日：2007-08-30

  The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

  这项发明涉及公式（1）的化合物及其药用盐，其制备方法和使用方法。
• HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR
  申请人：Uchida Hiroshi

  公开号：US20130079306A1

  公开（公告）日：2013-03-28

  A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

  提供了一种新型杂环化合物或其盐，用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式（1）表示：其中A代表烷基、环烷基、芳基或杂环基，基团A可能有取代基；环B代表5至8成员的单环杂环环或包含该单环杂环环的缩合环，环B可能有取代基；环C代表芳香环，环C可能有取代基；L代表包含3至5个原子的主链的连接物，所述原子选自碳原子、氮原子、氧原子和硫原子组成的群，其中主链中的至少一个原子是选自氮原子、氧原子和硫原子组成的杂原子，连接物L可能有取代基；n为0或1。
• [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2013192273A1

  公开（公告）日：2013-12-27

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物，其合成方法，包含这些化合物的药物组合物，以及它们的使用方法。在一个实施例中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病。
• [EN] NOVEL SULPHOXIMIDE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE QUINOLÉINE ET DE QUINAZOLINE SUBSTITUÉS PAR SULFOXIMIDE COMME INHIBITEURS DE KINASES
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2009080200A1

  公开（公告）日：2009-07-02

  Novel sulphoximide-substituted quinoline and quinazoline derivatives as kinase inhibitors The present invention relates to quinoline and quinazoline derivatives of the general formula (I) in which W, Y, R3 and R4 are indicated in the description and the claims, the use of the compounds of the general formula (I) for the treatment of various disorders, the preparation of compounds of the general formula (I), and intermediates useful in the preparation of compounds of the general formula (I).

  新型硫代羟胺取代的喹啉和喹唑啉衍生物作为激酶抑制剂。本发明涉及一般式(I)的喹啉和喹唑啉衍生物，其中W、Y、R3和R4在描述和权利要求中指示，所述一般式(I)化合物用于治疗各种疾病，制备一般式(I)化合物，以及制备一般式(I)化合物的有用中间体。